Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

10 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Home administration of maintenance pemetrexed for patients with advanced non-squamous non-small cell lung cancer: rationale, practicalities and phase II feasibility study design.
Lal R, Bourayou N, Hillerdal G, Nicolson M, Vikstrom A, Lorenzo M, D'yachkova Y, Barriga S, Visseren-Grul C. Lal R, et al. Among authors: bourayou n. Health Qual Life Outcomes. 2013 Oct 3;11:163. doi: 10.1186/1477-7525-11-163. Health Qual Life Outcomes. 2013. PMID: 24090033 Free PMC article. Clinical Trial.
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer.
Goetz MP, Toi M, Campone M, Sohn J, Paluch-Shimon S, Huober J, Park IH, Trédan O, Chen SC, Manso L, Freedman OC, Garnica Jaliffe G, Forrester T, Frenzel M, Barriga S, Smith IC, Bourayou N, Di Leo A. Goetz MP, et al. Among authors: bourayou n. J Clin Oncol. 2017 Nov 10;35(32):3638-3646. doi: 10.1200/JCO.2017.75.6155. Epub 2017 Oct 2. J Clin Oncol. 2017. PMID: 28968163 Clinical Trial.
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy.
Sledge GW Jr, Toi M, Neven P, Sohn J, Inoue K, Pivot X, Burdaeva O, Okera M, Masuda N, Kaufman PA, Koh H, Grischke EM, Frenzel M, Lin Y, Barriga S, Smith IC, Bourayou N, Llombart-Cussac A. Sledge GW Jr, et al. Among authors: bourayou n. J Clin Oncol. 2017 Sep 1;35(25):2875-2884. doi: 10.1200/JCO.2017.73.7585. Epub 2017 Jun 3. J Clin Oncol. 2017. PMID: 28580882 Clinical Trial.
[Chemotherapy-induced cardiotoxicity in the elderly].
Bernard M, Avenin D, Selle F, Gligorov J, Houssel P, Carette B, Bourayou N, Lokiec F, Carola E, Lotz JP. Bernard M, et al. Among authors: bourayou n. Bull Cancer. 2008 May 28;95 FMC Onco:F89-95. doi: 10.1684/bdc.2007.0533. Bull Cancer. 2008. PMID: 18511374 French.
A first-in-human phase I study of the PD-1 inhibitor, retifanlimab (INCMGA00012), in patients with advanced solid tumors (POD1UM-101).
Lakhani N, Cosman R, Banerji U, Rasco D, Tomaszewska-Kiecana M, Garralda E, Kornacki D, Li J, Tian C, Bourayou N, Powderly J. Lakhani N, et al. Among authors: bourayou n. ESMO Open. 2024 Apr;9(4):102254. doi: 10.1016/j.esmoop.2024.102254. Epub 2024 Feb 21. ESMO Open. 2024. PMID: 38387109 Free PMC article. Clinical Trial.
[Chemotherapy in the elderly: how and for whom?].
Avenin D, Selle F, Gligorov J, Japkowicz M, Houssel P, Carette B, Bernard M, Abbas F, Khalil A, Bourayou N, Lokiec F, Carola E, Saint-Jean O, Leblond V, Bouvard E, Lotz JP. Avenin D, et al. Among authors: bourayou n. Bull Cancer. 2008 May 28;95 FMC Onco:F28-36. doi: 10.1684/bdc.2007.0537. Bull Cancer. 2008. PMID: 18511364 French.